Fortrea Holdings Inc. (FTRE)vsVertex Pharmaceuticals Inc (VRTX)
FTRE
Fortrea Holdings Inc.
$23.14
-10.61%
HEALTHCARE · Cap: $2.14B
VRTX
Vertex Pharmaceuticals Inc
$540.00
+1.95%
HEALTHCARE · Cap: $126.66B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 370% more annual revenue ($12.59B vs $2.68B). VRTX leads profitability with a 35.0% profit margin vs -3.2%. FTRE appears more attractively valued with a PEG of 0.34. VRTX earns a higher WallStSmart Score of 64/100 (C+).
FTRE
Hold41
out of 100
Grade: D
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-39.5%
Fair Value
$8.31
Current Price
$23.14
$14.83 premium
Margin of Safety
+45.0%
Fair Value
$952.30
Current Price
$540.00
$412.30 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Operating margin of 2.6%
Weak financial health signals
ROE of -85.0% — below average capital efficiency
Revenue declined 4.5%
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : FTRE
The strongest argument for FTRE centers on PEG Ratio. PEG of 0.34 suggests the stock is reasonably priced for its growth.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : FTRE
The primary concerns for FTRE are Operating Margin, Piotroski F-Score, Return on Equity. Debt-to-equity of 2.13 is elevated, increasing financial risk.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
FTRE profiles as a turnaround stock while VRTX is a mature play — different risk/reward profiles.
FTRE carries more volatility with a beta of 1.91 — expect wider price swings.
VRTX is growing revenue faster at 12.5% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 41/100), backed by strong 35.0% margins and 12.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fortrea Holdings Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry. The company is headquartered in Durham, North Carolina.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?